Greyledge Technologies
Greyledge develops advanced quality control systems for processing biologic therapy products, enhancing scientific understanding and product optimization.
Founded
2010Greyledge develops advanced quality control systems for processing biologic therapy products, enhancing scientific understanding and product optimization.
Founded with a mission to refine cellular medicine through biodata analytics, Greyledge Technologies specializes in autologous cell therapeutics, including Platelet Rich Plasma (PRP) and Bone Marrow Concentrate (BMC). The company develops advanced quality control systems to process biologic therapy products derived from a patient’s own blood or bone marrow tissue. This innovative approach allows for precise measurement and quantification of complex cell populations, enabling customized treatments tailored to individual patients and specific clinical applications.
Greyledge Technologies has garnered trust from leading medical professionals and institutions due to its pioneering methods in biodata analytics and product optimization. Notable achievements include significant advancements in the scientific understanding of cell-based therapies and their applications in treating orthopedic conditions. By combining detailed product analytics with patient-reported outcomes, Greyledge has made a substantial impact on the field of cellular medicine, setting new standards for quality and efficacy in biologic therapies.
Companies similar to Greyledge Technologies include EndoCellutions, Platelet BioGenesis, Circle Biologics and Trailhead Biosystems.
Greyledge Technologies was founded in 2010.
Greyledge Technologies' headquarters is located in Lone Tree, CO, US.
Greyledge Technologies' most recent funding round was for $4.3M (USD) in April 2022.
As of Apr 4, 2022, Greyledge Technologies has raised a total of $6.8M (USD).
Greyledge Technologies has 18 employees as of Feb 5, 2024.
Circle Biologics
